לברסט

Država: Izrael

Jezik: hebrejski

Izvor: Ministry of Health

Aktivni sastojci:

LETROZOLE 2.5 MG

Dostupno od:

RAFA LABORATORIES LTD

ATC koda:

L02BG04

Farmaceutski oblik:

FILM COATED TABLETS

Administracija rute:

PER OS

Proizveden od:

SIEGFRIED GENERICS ( MALTA) LTD

Terapijska grupa:

LETROZOLE

Terapijske indikacije:

Letrozole tablets are indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined locally advanced or metastatic breast cancer. Letrozole is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Datum autorizacije:

2012-04-01